Skip to main content
TGTX logo

TG Therapeutics, Inc.

TGTXNASDAQHealthcareBiotechnology

$54.79Today:- (-)1Y +58.73%

As of Oct 26, 2026 close

Market cap
$8.62B
P/E (TTM)
19.52
Forward P/E
9.60
Dividend yield
-
52-week range
$26.76$59.30
Volume (live)
-
Avg. volume (3M)
1.73M

TG Therapeutics (TGTX) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), TG Therapeutics had a P/E ratio of 9.75 (down from 184.75), return on equity of 102.8% (up from 12.2%), debt-to-equity of 0.39 (down from 1.14) and a current ratio of 4.10 (down from 6.25). A current ratio of 4.10 means current assets exceed current liabilities.

TG Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio9.75184.75190.66---
Forward P/E20.2945.21134.45---
P/S Ratio7.0713.1310.34568.84371.9644096.70
P/B Ratio6.7219.4315.0527.0410.4912.91
Price/Tangible Book6.7219.4315.0527.4110.5312.93
PEG Ratio0.140.37----
Enterprise Value Ratios
EV/Revenue7.2712.879.83535.24322.8242698.06
EV/EBITDA36.32100.79110.20---
EV/EBIT36.34100.95111.33---
Profitability & Returns
Return on Equity (ROE)102.75%12.22%11.57%-151.36%-92.03%-100.14%
Return on Assets (ROA)9.39%5.78%4.93%-47.61%-42.87%-43.36%
Return on Invested Capital (ROIC)26.63%34.84%116.52%---
Return on Capital Employed (ROCE)13.60%8.60%7.50%-155.50%-109.70%-50.80%
Leverage & Solvency Ratios
Debt/Equity0.391.140.691.420.340.08
Debt/EBITDA2.035.744.82---
Liquidity Ratios
Current Ratio4.106.255.923.165.066.99
Quick Ratio2.914.855.003.044.836.92
Efficiency Ratios
Asset Turnover0.750.720.890.010.010.00
Inventory Turnover0.850.51----
Yield & Distribution Ratios
Earnings Yield10.26%0.54%0.52%-14.13%-13.99%-4.17%
FCF Yield-0.57%-0.94%-1.30%-11.12%-11.90%-3.21%
Buyback Yield-0.67%-7.96%-9.67%-2.41%-14.64%-30.51%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TG Therapeutics Financial Ratios

What is TG Therapeutics's P/E ratio?

TG Therapeutics's P/E ratio was 9.75 for fiscal 2025 (period ended Dec 31, 2025). It was 184.75 a year earlier.

What is TG Therapeutics's return on equity?

TG Therapeutics's return on equity (ROE) was 102.8% for fiscal 2025 (period ended Dec 31, 2025). It was 12.2% a year earlier.

What is TG Therapeutics's debt-to-equity ratio?

TG Therapeutics's debt-to-equity ratio was 0.39 for fiscal 2025 (period ended Dec 31, 2025). It was 1.14 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition